| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2010-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101751216-B1 |
| titleOfInvention |
Pharmaceutical dosage form for oral administration of a Bcl-2 family inhibitor |
| abstract |
The present invention relates to a process for the preparation of N- (4- (4 - ((2- (4-chlorophenyl) -5,5-dimethyl-1-cyclohex- Benzyl) -4 - ((1 R) -3- (morpholin-4-yl) -1 - ((phenylsulfanyl) methyl) Solvate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizing agent, in the manufacture of a medicament. The invention further relates to a process for the manufacture of said pharmaceutical dosage forms and the use of said dosage form for the treatment of proliferative disorders. |
| priorityDate |
2009-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |